title: NICE guidance on ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation.
authors.affiliation: National Institute for Health and Care Excellence, London SW1A 2BU, UK. Electronic address: boglarka.mikudina@nice.org.uk.
authors.forename: Boglarka
authors.initials: B
authors.lastname: Mikudina
authors.affiliation: National Institute for Health and Care Excellence, London SW1A 2BU, UK.
authors.forename: Melinda
authors.initials: M
authors.lastname: Goodall
authors.affiliation: National Institute for Health and Care Excellence, London SW1A 2BU, UK.
authors.forename: Amanda I
authors.initials: AI
authors.lastname: Adler
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D002872:Chromosome Deletion; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics; D009154:Mutation; D010880:Piperidines; D017410:Practice Guidelines as Topic; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: D010880:Piperidines; D011720:Pyrazoles; D011743:Pyrimidines; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C551803:ibrutinib; D000225:Adenine